Lineage Cell Therapeutics, Inc. (LCTX) Gross profit 2016–2024
Lineage Cell Therapeutics, Inc. (LCTX) annual gross profit history from SEC filings — each fiscal year as reported.
$9.2MFY2024 · since FY2016: $5.6M → $9.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $9.2M | +10.8% |
| FY2023 | $8.3M | -40.8% |
| FY2022 | $14.0M | +379.4% |
| FY2021 | $2.9M | +102.3% |
| FY2020 | $1.4M | -53.6% |
| FY2019 | $3.1M | -33.8% |
| FY2018 | $4.7M | +42.4% |
| FY2017 | $3.3M | -40.9% |
| FY2016 | $5.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice